ClinicalTrials.gg
CompletedNCT07242612Updated Aug 13, 2026

Bone Turnover Markers and Treatment Efficacy in Postmenopausal Osteoporosis

An interventional study of Alendronate, Ibandronate; Risedronate and Teriparatide in Osteoporosis and Osteoporosis, Postmenopausal, sponsored by Khyber Medical University Peshawar. Completed at 1 site in Pakistan. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-08-13.

Primary conditionOsteoporosis, PostmenopausalRegistry: OsteoporosisReclassifiedWhy we changed it
Registry
Osteoporosis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Osteoporosis, Postmenopausal
Why
  1. The study's listed conditions name Osteoporosis, Postmenopausal, a narrower term within Osteoporosis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Khyber Medical University Peshawar · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies testing teriparatide in Osteoporosis, Postmenopausal — 1 open to participants now, 1 under way, none of them phase 3. Teriparatide · Osteoporosis, Postmenopausal.

Enrollment
19th of 22
40 · median 75
Started
2025
with 1 other
No phase
Only one
of the 23
Registered
23rd of 23
by date
Lead sponsor
1 of 23
Khyber Medical University Peshawar

Among the 23 studies testing teriparatide in Osteoporosis, Postmenopausal, this one is the 19th largest by enrollment of the 22 interventional ones that give a count, is one of 2 that started in 2025, is the only one with no phase, and was the 23rd registered.

Osteoporosis, Postmenopausal

334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.

Browse Osteoporosis, Postmenopausal studies →

Open to participants now

1 of the 23 studies testing teriparatide in Osteoporosis, Postmenopausal is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About teriparatide

Teriparatide: first FDA approval 2002 (FORTEO), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Osteoporosis, Postmenopausal studies recruiting now, 8 (40%) set no upper age limit and 8 (40%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing teriparatide in Osteoporosis, Postmenopausal, or all of them as a file.
02

Study summary

This study investigates the use of blood tests known as Bone Turnover Markers (BTMs) to quickly monitor the effectiveness of osteoporosis treatment in postmenopausal women. Osteoporosis, which weakens bones and increases fracture risk, is typically monitored using a DEXA scan to measure bone density (BMD), but this method changes slowly. BTMs may show a response to medication within just 3 to 6 months. In this randomized controlled trial, 40 postmenopausal women with osteoporosis will be assigned to receive either antiresorptive drugs (which slow bone loss) or anabolic drugs (which build new bone), along with calcium and vitamin D. The study will compare how these treatments affect BTMs and BMD over six months to determine if BTMs can serve as an early and reliable indicator of treatment success, which could be particularly useful in regions like Pakistan where access to repeated DEXA scans is limited.

Read the detailed description

A randomized controlled trial will be conducted to evaluate the association between selective BTM and the efficacy of different drug therapies in primary postmenopausal osteoporotic women. The study is motivated by the high prevalence of osteoporosis in this demographic in Pakistan and the limitations of the current gold standard, BMD measured by DEXA scan, which reflects changes in bone strength at a delayed rate. BTMs, being biochemical indicators of bone formation and resorption, offer a dynamic and rapid assessment of bone metabolic activity, potentially providing an early measure of treatment response within months rather than years. The trial will enroll 40 eligible women over 50, who will be randomly and blindly assigned to one of two treatment groups: one receiving antiresorptive drugs (such as Alendronate) and the other receiving anabolic drugs (Teriparatide), both supplemented with calcium and vitamin D for a six-month period. The primary outcomes include the comparative change in specific BTMs (BsALP, TRACP-5b, and Sclerostin) at three and six months, and the change in BMD at six months. Secondary outcomes will assess the correlation between BTM and BMD changes, as well as fracture incidence and quality of life. By analyzing these parameters, the study aims to generate valuable evidence for the utility of BTMs in guiding and monitoring osteoporosis treatment in a Pakistani clinical setting, potentially leading to more responsive and personalized patient management.

03

Conditions studied

  • Osteoporosis
  • Osteoporosis, Postmenopausal

Browse trials for

Keywords

  • Bone Turnover Markers
  • Bone Density
  • Postmenopausal Osteoporosis
  • DEXA Scan
04

In context

Osteoporosis, Postmenopausal Reclassified

334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.

This study's enrollment of 40 is below the median of 119 across 264 interventional studies indexed under Osteoporosis, Postmenopausal.

Browse Osteoporosis, Postmenopausal studies →

Lead sponsor

Khyber Medical University Peshawar is the lead sponsor of 54 studies on the registry; 11 are open to participants now.

Compared within Osteoporosis, Postmenopausal, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Osteoporosis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women (at least one year since last menstrual cycle).
  • Age greater than 50 years.
  • Diagnosis of primary osteoporosis.
  • Currently not on any anti-osteoporosis medications.
  • Not taking Calcium or Vitamin D supplements.
  • Volunteer to participate and provide .

Exclusion criteria

Exclusion Criteria:

  • Women with multiple vertebral fractures or severe lumbar degenerative changes.
  • Use of hormone/estrogen therapy, calcitonin, oral bisphosphonates, IV ibandronate, IV Zoledronic acid, denosumab, or teriparatide within the past 18 months.
  • Use of (short or long-term).
  • History of hyperthyroidism, hypothyroidism, liver disease, kidney disease, or tumors.
  • Presence of secondary causes of osteoporosis (e.g., eating disorders, celiac disease, diabetes, hematologic disorders).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Anabolic Therapy Group

    Participants in this group will receive the anabolic drug Teriparatide 20 mcg, administered as a daily subcutaneous injection, for a duration of 6 months. In addition, all participants in this arm will receive daily Calcium and Vitamin D supplements.

    Drug: Teriparatide

  • Active comparator
    Antiresorptive Therapy Group

    Participants will receive one of the following oral antiresorptive drugs for 6 months: Alendronate 70mg weekly, Ibandronate 150mg monthly, or Risedronate 150mg monthly. All participants will also receive Calcium and Vitamin D supplementation.

    Drug: Alendronate, Ibandronate; Risedronate

Interventions

  • DrugAlendronate, Ibandronate; Risedronate

    Drug pages: AlendronateStudies of AlendronateAlendronate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Ibandronic AcidStudies of Ibandronic AcidIbandronic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Risedronic AcidStudies of Risedronic AcidRisedronic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Oral bisphosphonate tablets. Participants will receive one of the following specific regimens: Alendronate 70mg taken once per week, Ibandronate 150mg taken once per month, or Risedronate 150mg taken once per month. This is combined with daily Calcium and Vitamin D supplementation. The total treatment duration is 6 months.

    Also known as: Fosamax; Bonviva; Actonel

  • A solution for subcutaneous injection. The dosage is 20 micrograms (mcg) injected once daily. This is combined with daily Calcium and Vitamin D supplementation. The total treatment duration is 6 months.

    Also known as: Forteo

07

What researchers measure

Primary outcomes

  1. Change in Bone Turnover Markers (BTMs)

    Mean change from baseline in the serum levels of specific bone turnover markers, including the bone formation marker Bone-Specific Alkaline Phosphatase (BsALP) and the bone resorption marker Tartrate-Resistant Acid Phosphatase 5b (TRACP-5b), and the osteocyte marker Sclerostin.

    Time frame: Baseline, 3 months, and 6 months.

  2. Change in Bone Mineral Density (BMD)

    Mean change from baseline in Bone Mineral Density (BMD) T-score as measured by Dual-Energy X-ray Absorptiometry (DEXA) scans at the hip, spine, and femoral neck.

    Time frame: Baseline and 6 months.

Secondary outcomes

  1. Incidence of New Fractures

    The number of participants who experience any new fragility fractures during the study period.

    Time frame: Through study completion, an average of 6 months.

08

Study locations

1 site
  • Northwest General Hospital
    Peshawar, Khyber Pakhtunkhwa 25000, Pakistan
09

References and documents

Publications

  • Lorentzon M, Branco J, Brandi ML, Bruyere O, Chapurlat R, Cooper C, Cortet B, Diez-Perez A, Ferrari S, Gasparik A, Herrmann M, Jorgensen NR, Kanis J, Kaufman JM, Laslop A, Locquet M, Matijevic R, McCloskey E, Minisola S, Pikner R, Reginster JY, Rizzoli R, Szulc P, Vlaskovska M, Cavalier E. Algorithm for the Use of Biochemical Markers of Bone Turnover in the Diagnosis, Assessment and Follow-Up of Treatment for Osteoporosis. Adv Ther. 2019 Oct;36(10):2811-2824. doi: 10.1007/s12325-019-01063-9. Epub 2019 Aug 22. PubMed 31440982 ↗
  • Bhattoa HP, Cavalier E, Eastell R, Heijboer AC, Jorgensen NR, Makris K, Ulmer CZ, Kanis JA, Cooper C, Silverman SL, Vasikaran SD; IFCC-IOF Committee for Bone Metabolism. Analytical considerations and plans to standardize or harmonize assays for the reference bone turnover markers PINP and beta-CTX in blood. Clin Chim Acta. 2021 Apr;515:16-20. doi: 10.1016/j.cca.2020.12.023. Epub 2020 Dec 28. PubMed 33382995 ↗
  • Nadeem S, Pervez A, Abid MA, Khalid RN, Rizvi NA, Aamdani SS, Ayub B, Mustafa MA, Ahmed S, Riaz M, Irfan K, Noordin S, Jafri L, Majid H, Umer M, Zehra N, Sheikh A, Haider AH, Khan AH. GRADE-ADOLOPMENT of clinical practice guideline for postmenopausal osteoporosis management-a Pakistani context. Arch Osteoporos. 2023 May 19;18(1):71. doi: 10.1007/s11657-023-01258-2. PubMed 37204537 ↗
  • Jorgensen NR, Mollehave LT, Hansen YBL, Quardon N, Lylloff L, Linneberg A. Comparison of two automated assays of BTM (CTX and P1NP) and reference intervals in a Danish population. Osteoporos Int. 2017 Jul;28(7):2103-2113. doi: 10.1007/s00198-017-4026-z. Epub 2017 Apr 28. PubMed 28455749 ↗
  • Moller AMJ, Delaisse JM, Olesen JB, Canto LM, Rogatto SR, Madsen JS, Soe K. Fusion Potential of Human Osteoclasts In Vitro Reflects Age, Menopause, and In Vivo Bone Resorption Levels of Their Donors-A Possible Involvement of DC-STAMP. Int J Mol Sci. 2020 Sep 2;21(17):6368. doi: 10.3390/ijms21176368. PubMed 32887359 ↗
  • Patel D, Worley JR, Volgas DA, Crist BD. The Effectiveness of Osteoporosis Screening and Treatment in the Midwest. Geriatr Orthop Surg Rehabil. 2018 Mar 29;9:2151459318765844. doi: 10.1177/2151459318765844. eCollection 2018. PubMed 29623238 ↗
  • Rizzoli R. Postmenopausal osteoporosis: Assessment and management. Best Pract Res Clin Endocrinol Metab. 2018 Oct;32(5):739-757. doi: 10.1016/j.beem.2018.09.005. Epub 2018 Sep 22. PubMed 30449552 ↗
  • Cosman F, McMahon D, Dempster D, Nieves JW. Standard Versus Cyclic Teriparatide and Denosumab Treatment for Osteoporosis: A Randomized Trial. J Bone Miner Res. 2020 Feb;35(2):219-225. doi: 10.1002/jbmr.3850. Epub 2019 Oct 23. PubMed 31419313 ↗

Individual participant data

Plan to share: Yes — A definitive plan for sharing individual participant data has not been established. The data collected, including de-identified individual participant records for primary and secondary outcomes, may be made available upon reasonable request after the primary results are published.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data may become available beginning 6 months after the publication of the primary study findings and will be accessible for a period of 3 years.

Access criteria: Access to IPD will be considered for researchers who provide a methodologically sound proposal. Requests should be directed to the corresponding author. Approval will be subject to review by the study's supervisory committee and a signed data sharing agreement.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2025 to primary completion in Mar 2026, 5 months.

Of 48 non-industry interventional studies with no phase under Osteoporosis, Postmenopausal, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 34. This study's 5 months is below that.

Counting every sponsor, half of 51 studies reached it within 17 months; a quarter within 9 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2025
First posted
Nov 21, 2025
StartActual
Oct 1, 2025
Primary completionActual
Mar 25, 2026
CompletionActual
Apr 15, 2026
Last update
Aug 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07242612
Lead sponsor
Khyber Medical University Peshawar
Responsible party
Sponsor
First posted
Nov 21, 2025
Start date
Oct 1, 2025
Primary completion
Mar 25, 2026
Completion
Apr 15, 2026
Last update
Aug 13, 2026

Study contacts

Asma Mehmood, PhD Scholar
principal investigator · Institute of Basic Medical Sciences, Khyber Medical University
Rubina Nazli, PhD
study director · Institute of Basic Medical Sciences, Khyber Medical University
Arshad Hussain, M.D Consultant
principal investigator · Northwest General Hospital, Peshawar
Ehtesham Khan, PhD
principal investigator · InsInstitute of Basic Medical Sciences, Khyber Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Teriparatide

Start the discussion